


# Amendments to the Claims

Claims 1-17. (Cancelled)

18. (New) A compound of formula I:



I;

wherein:

R<sup>1</sup> is selected from OH or NH<sub>2</sub> and is at the ortho-position relative to heterocycle X;

R<sup>2</sup> is selected from OCH<sub>3</sub> and H and is at the para-position relative to heterocycle X;


R<sup>3</sup> is H;

X is a 5-membered aromatic heterocycle that is optionally substituted with C<sub>1</sub>-C<sub>4</sub> alkyl; wherein said heterocycle contains at least two or three heteroatoms selected from N, S and O wherein at least one heteroatom must be N and wherein said heterocycle may not be 1,3,4-oxadiazole; and

n is 2, 3, 4, 5, 6 or 7;


or a pharmaceutical salt thereof.

19. (New) The compound of claim 18 of the formula:




or a pharmaceutical salt thereof.

20. (New) The compound of claim 18 which is:




or a pharmaceutical salt thereof.

21. (New) The compound of claim 18 which is:




or a pharmaceutical salt thereof.

22. (New) The compound of claim 18 which is:




or a pharmaceutical salt thereof.

23. (New) The compound of claim 18 which is:




or a pharmaceutical salt thereof.

24. (New) The compound of claim 18 which is:




or a pharmaceutical salt thereof.

25. (New) The compound of claim 18 which is:



or a pharmaceutical salt thereof.

26. (New) The compound of claim 18 which is:



or a pharmaceutical salt thereof.

27. (New) A pharmaceutical composition comprising:

- a) a compound of claim 18 or a pharmaceutical salt thereof; and
- b) a GLP-1 compound.

28. (New) The composition of claim 27, wherein the GLP-1 compound is Val<sup>8</sup>-Glu<sup>22</sup>-GLP-1(7-37)OH.

29. (New) A pharmaceutical composition comprising:

- a) a compound of claim 18 or a pharmaceutical salt thereof; and
- b) an MC4 agonist peptide.